



**DIAGNOSTIC AND THERAPEUTIC CENTER OF ATHENS "HYGEIA SA"**  
 SA Registration No. 13165/06/B/86/14  
 4 KIFISIAS AVENUE & ERYTHROU STAVROU STR., 15123 MAROUSI, ATHENS  
 Data and information for the period from 01 January 2007 to 30 June 2007  
 (according to decision No. 2/396/31.08.2006 of the Board of Directors of the Capital Market Committee)

The following data and information aim at providing a general insight about the financial status and results of D.T.C.A. "Hygeia SA". Consequently, before proceeding to any investment decision or other transaction with the Company, we suggest the reader visited the Company's internet address, which presents the periodic financial statements provided for by the International Accounting Standards, as well as the review report of the Sworn-in Auditor-Accountant, wherever this is necessary.

GENERAL INFORMATION ABOUT THE COMPANY					INCOME STATEMENT				
Address of Company's Registered Office 4 Kifisias & Erythrou Stavrou Str., 151 23 Marousi, Athens					Amounts in Euros				
Societies Anonymes Registration Number 13165/06/B/86/14					Group				
Competent Prefecture (or Court of First Instance) Ministry of Development & Commerce					01/01-30/06/2007 01/01-30/06/2006 01/04-30/06/2007 01/04-30/06/2006				
Composition of the Board of Directors President: Vgenopoulos Andreas					Turnover 57,181,259 47,595,991 29,406,791 24,185,605				
Vice President: Charamis Themistocles					Gross profit 12,253,173 6,009,916 4,987,961 3,401,739				
BoD Members: Bouchoris Paschalis-Chief Executive Officer, Souvatzoglou Areti, Rapp Antony					Earnings before taxes, from financing, investment results and depreciations 12,827,663 5,826,516 5,293,736 2,614,472				
Non executive members: Kyprianidis Anastasios, Leventi Aikaterini, Maroudis Christos, Karatzenis Fotios, Seitanidis Vasileios, Kosmidis Paraskevas					Earnings before taxes, from financing and investment results 9,684,721 2,556,440 3,723,295 980,604				
Independent non executive members: Editidis Alexandros, Moustakas Mel.					Profit / (loss) before taxes 10,214,142 1,489,566 3,860,106 435,549				
Date of Approval of Financial Statements (out of which the following concise data were drawn) 27.07.2007					Minus taxes (1,649,603) (654,904) (919,275) (199,116)				
Sworn-In Auditors - Accountants Vasileios Kazas (SOEL Reg. No. 13821) Manolis Michailios (SOEL Reg. No. 25131)					Profit / (loss) after taxes 8,564,539 834,662 2,940,831 236,433				
Audit Company Grant Thorton SA (SOEL Reg.No 127)					Allocated to:				
Auditors' Audit Report Type On accord					Company shareholders 8,562,540 812,124 2,948,737 213,895				
Method of Filling in the Cash Flows Statement Indirect method (consolidated and non-consolidated)					Minority interest 1,999 22,538 (7,905) 22,538				
Company's website www.hygeia.gr					Profit / (loss) after taxes er share –basic (in €) 0.13 0.02 0.05 0.004				
BALANCE SHEET					STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD				
Amounts in Euros					Amounts in Euros				
Group Company					Group Company				
30/06/2007 12/31/2006 30/06/2007 12/31/2006					30/06/2007 30/06/2006 30/06/2007 30/06/2006				
ASSETS					Operating activities				
Fixed Assets 162,596,170 163,908,810 156,606,021 155,134,825					Earnings before taxes 10,214,142 1,489,566 10,521,958 1,019,506				
Inventories 3,204,427 2,859,319 2,925,268 2,745,087					Plus / minus adjustments for: Depreciations 3,142,942 3,270,076 3,103,392 3,241,672				
Receivables from clients 30,343,160 27,381,373 30,496,755 27,170,139					Provisions 1,165,752 1,397,364 1,133,479 1,393,350				
Other assets 7,886,436 5,294,501 2,851,449 4,106,741					Income from using provisions of previous financial years (18,825) 0 0 0				
<b>TOTAL ASSETS 204,030,193 199,444,002 192,879,493 189,156,792</b>					Results (income, expenses, earnings and loss) from investment activities (1,791,946) (940,028) (2,421,669) (839,099)				
LIABILITIES					Payable interests and relevant expenses 1,262,525 1,954,786 1,249,838 1,951,968				
Long-term liabilities 43,958,897 45,111,264 36,561,568 37,659,242					Plus / minus adjustments for changes in working capital accounts or changes related to operating activities:				
Short-term bank liabilities 16,742,792 23,702,659 16,712,930 23,672,578					Decrease / (increase) in inventories (345,108) (623,881) (180,182) (672,409)				
Other short-term liabilities 33,410,141 29,795,255 32,097,691 29,251,079					Decrease / (increase) in receivables (6,919,600) (2,798,782) (4,024,087) (2,520,913)				
Total liabilities (a) 94,111,830 98,609,178 85,372,190 90,582,900					(Decrease) / increase in liabilities (minus bank liabilities) 6,125,879 2,424,854 2,691,159 2,208,314				
Share Capital 26,322,000 26,322,000 26,322,000 26,322,000					Decrease / (increase) in provisions (2,198,512) (133,000) (2,162,337) (133,000)				
Other assets of Company shareholders' net worth 82,944,746 74,463,206 81,185,303 72,251,893					Decrease / (increase) in other long-term receivables (59,943) (43,494) (26,801) (45,294)				
Total net worth of Company's shareholders (b) 109,266,746 100,785,206 107,507,303 98,573,893					Minus: Interests payable and relevant expenses paid (966,308) (1,906,377) (953,621) (1,903,559)				
Minority interest (c) 651,617 49,618 0 0					Taxes paid (33,727) (111,634) 0 0				
Total Net Worth (d) = (b) + (c) 109,918,363 100,834,824 107,507,303 98,573,893					<b>Total inflow / (outflow) from operating activities (a) 9,577,271 3,979,450 8,931,129 3,700,536</b>				
<b>TOTAL LIABILITIES (a) + (d) 204,030,193 199,444,002 192,879,493 189,156,792</b>					Investment activities				
CASH FLOW STATEMENT					Acquisition of subsidiaries, associates, ventures and other investments (1,471,738) (58,939,264) (2,926,738) (59,250,417)				
Amounts in Euros					Purchase of tangible and intangible fixed assets (1,693,676) (993,091) (1,621,049) (988,436)				
Group Company					Revenue from the sale of tangible and intangible fixed assets 0 78,279 0 78,279				
01/01-30/06/2007 01/01-30/06/2006 01/01-30/06/2007 01/01-30/06/2006					Loans granted to affiliated parties (200,000) 0 (200,000) 0				
Operating activities					Interests Received 65,426 13,061 44,838 9,245				
Earnings before taxes 10,214,142 1,489,566 10,521,958 1,019,506					Dividends Received 3,084,974 1,332,758 1,835,756 7,600				
Plus / minus adjustments for: Depreciations 3,142,942 3,270,076 3,103,392 3,241,672					<b>Total inflow / (outflow) from investment activities (b) (215,015) (58,508,257) (2,867,193) (60,143,729)</b>				
Provisions 1,165,752 1,397,364 1,133,479 1,393,350					Financing activities				
Income from using provisions of previous financial years (18,825) 0 0 0					Issuing of common shares 645,000 0 0 0				
Results (income, expenses, earnings and loss) from investment activities (1,791,946) (940,028) (2,421,669) (839,099)					Net inflows / (outflows) of loans (7,178,008) 58,896,735 (7,178,008) 58,896,735				
Payable interests and relevant expenses 1,262,525 1,954,786 1,249,838 1,951,968					Payments of liabilities from financing leases (sinking funds) (156,313) (355,385) (141,220) (342,497)				
Plus / minus adjustments for changes in working capital accounts or changes related to operating activities:					Dividends paid (81,000) (4,844) 0 (4,844)				
Decrease / (increase) in inventories (345,108) (623,881) (180,182) (672,409)					<b>Total inflow / (outflow) from financing activities (c) (6,770,321) 58,536,506 (7,319,228) 58,549,394</b>				
Decrease / (increase) in receivables (6,919,600) (2,798,782) (4,024,087) (2,520,913)					Total increase / (decrease) in cash flow and cash equivalents of the period (a) + (b) + (c) 2,591,935 4,007,699 (1,255,292) 2,106,201				
(Decrease) / increase in liabilities (minus bank liabilities) 6,125,879 2,424,854 2,691,159 2,208,314					Cash flow and cash equivalents in the beginning of the period 5,294,501 1,880,659 4,106,741 1,395,839				
Decrease / (increase) in provisions (2,198,512) (133,000) (2,162,337) (133,000)					<b>Cash flow and cash equivalents at the end of the period 7,886,436 5,888,358 2,851,449 3,502,040</b>				
Decrease / (increase) in other long-term receivables (59,943) (43,494) (26,801) (45,294)									
Minus: Interests payable and relevant expenses paid (966,308) (1,906,377) (953,621) (1,903,559)									
Taxes paid (33,727) (111,634) 0 0									
<b>Total inflow / (outflow) from operating activities (a) 9,577,271 3,979,450 8,931,129 3,700,536</b>									
Investment activities									
Acquisition of subsidiaries, associates, ventures and other investments (1,471,738) (58,939,264) (2,926,738) (59,250,417)									
Purchase of tangible and intangible fixed assets (1,693,676) (993,091) (1,621,049) (988,436)									
Revenue from the sale of tangible and intangible fixed assets 0 78,279 0 78,279									
Loans granted to affiliated parties (200,000) 0 (200,000) 0									
Interests Received 65,426 13,061 44,838 9,245									
Dividends Received 3,084,974 1,332,758 1,835,756 7,600									
<b>Total inflow / (outflow) from investment activities (b) (215,015) (58,508,257) (2,867,193) (60,143,729)</b>									
Financing activities									
Issuing of common shares 645,000 0 0 0									
Net inflows / (outflows) of loans (7,178,008) 58,896,735 (7,178,008) 58,896,735									
Payments of liabilities from financing leases (sinking funds) (156,313) (355,385) (141,220) (342,497)									
Dividends paid (81,000) (4,844) 0 (4,844)									
<b>Total inflow / (outflow) from financing activities (c) (6,770,321) 58,536,506 (7,319,228) 58,549,394</b>									
Total increase / (decrease) in cash flow and cash equivalents of the period (a) + (b) + (c) 2,591,935 4,007,699 (1,255,292) 2,106,201									
Cash flow and cash equivalents in the beginning of the period 5,294,501 1,880,659 4,106,741 1,395,839									
<b>Cash flow and cash equivalents at the end of the period 7,886,436 5,888,358 2,851,449 3,502,040</b>									
ADDITIONAL DATA AND INFORMATION					Sales of products and services 254,582 993,752				
1. The following companies are included in the consolidation:					Purchases of products and services 3,933,787 3,460,534				
Company Name Seat Activity Participation percentage Consolidation method Participation relationship Tax unaudited financial years					Receivables 317,902 549,744				
HYGEIA SA Greece Health Services PARENT Total PARENT 2003-2007					Liabilities 12,218,863 15,138,302				
ALAN MEDICAL SA Greece Trade in medical equipment 100,00% Total Direct 2006-2007					Transactions and payments of chief executive officers and administration members 931,140 855,889				
MAGNETIC HYGEIA DIAGNOSTIC PRESENTATIONS SA Greece Health services 20,00% Net worth Direct 2005-2007					Receivables from chief executive officers and administration members 20,339 0				
ANIZ SA Greece Operation of restaurant refreshment rooms 70,00% Total Direct 2007					Liabilities towards chief executive officers and administration members 0 0				
MITERA HOLDINGS SA Greece Participation in MITERA SA 100,00% Total Direct 2003-2007					8. The Parent and the Group's Financial Statements of 30.06.2007 have been approved by the company's Board of Directors on 27.07.2007.				
MITERA SA Greece Health services 24,84% Net worth Direct and Indirect 2006-2007					9. No encumbrances on the company's fixed assets exist.				
LITO SA Greece Health services 18,00% Net worth Indirect 2006-2007					10. Some of the sums of 30.06.2007, were reclassified for presentation purposes (more information is given in the company's explicative notes).				
LITO HOLDINGS SA Greece Participation in LITO SA 18,34% Net worth Indirect 2004-2007					11. The profits per share have been estimated based on the average weighted number on the total number of shares.				
ALPHA - LAB Greece Health services 18,00% Net worth Indirect 2004-2007									
LITO - LAB Greece Health services 8,84% Net worth Indirect 2006-2007									
HYGEIA HOSPITAL - TIRANA SA Albania Health services 80,00% Total Direct 2006									
Y-PHARMA SA Greece Trade in pharmaceutical products and products of general medical use 85,00% Total Direct 2007									
STEM HEALTH SA Greece Biotechnology 50,00% Total Direct 2007									
The consolidated financial statements include the following companies for the first time, because of the audits conducted: a) STEM HEALTH SA, founded on 29/03/2007, with a percentage of 50%; b) Y PHARMA SA, founded on 03/04/2007, with a percentage of 85%; and c) HYGEIA HOSPITAL - TIRANA SA, founded on 25/04/2007, with a percentage of 80%.									
2. On 14/02/2007, the Company's Board of Directors decided to participate in the increase of the Share Capital of associate company MITERA PRIVATE GENERAL OBSTETRICS - GYNECOLOGICAL & PEDIATRIC CLINIC SA, which was decided at the Extraordinary Meeting of its shareholders on 13.1.2007, by paying a) the amount of seven hundred twenty three thousand six hundred and sixty four euros and thirty eight cents (723.664,38) in order to receive 289.466 shares corresponding to the shareholders' pre-emption rights that the company directly possesses and b) the amount of seven hundred forty eight thousand twenty three euros and twenty cents (748.023,20), in order to receive 299.229 shares from the undistributed shares of the increase of the Share Capital, that shall arise from the non-exercise of pre-emption rights by subsidiary SOCIETE ANONYME HOLDINGS OF HEALTH SERVICES & INVESTMENTS, which is owned 100% by the Company. Consequently, after covering the increase of MITERA SA share capital by a percentage of 24,84%, on 31/3/2007, the company has a direct participation percentage of 13,04% in MITERA SA and an indirect participation percentage through its 100% owned subsidiary MITERA HOLDINGS SA of 11,80%.									
3. The acquisition of the aforementioned shares was completed within February 2007.									
4. The repeating General meeting of the shareholders was held on 09/07/2007 and it was unanimously decided to increase the Company's share capital through contribution in kind and in particular through a contribution of up to 27.231.376 shares of the Societe Anonyme called "MITERA PRIVATE GENERAL OBSTETRICS - GYNECOLOGICAL & PEDIATRIC CLINIC SOCIETE ANONYME" ("MITERA SA") from its shareholders. Issuing of new common registered shares at a buying price above par and modification of article 5 (Share Capital - Shares) of the Company's Articles of Association. Abolition of the pre-emption rights of old shareholders upon increase of share capital as to the shares that shall be issued, in favor of "MITERA SA" shareholders, who shall contribute with their shares. Submission and approval of article 9 of Act 2190/1920 in the Committee's report. Determination of the shares distribution procedure and of the terms of increase. Right to receive the dividend of shares coming from the increase of share capital. Entry of the new shares issued after capital share increase for negotiation in the Athens Stock Exchange. Authorization of the Company's Board of Directors to regulate all issues regarding the drafting of a Prospectus, the granting of licenses and approvals from the Capital Market Committee and the Stock Exchange of Athens, the entry of the new shares in the Athens Stock Exchange and any relevant issues. It was decided to increase the Company's share capital by 25.679.187,65 euros by issuing 62.632.165 new registered shares each having a nominal value of 0,41 euros and a buying price above par of 3,60 euros, with contribution in kind and, in particular, with a contribution of 27.231.376 shares of "MITERA SA" with a nominal value of 0,60 euros and to modify the Articles of Partnership accordingly. Approval to abolish the pre-emption rights of old shareholders as to the total number of shares that shall be issued upon increase of share capital and decision to distribute the new shares to "MITERA SA" shareholders, who shall offer their shares. The shareholders of "MITERA SA" are entitled to have 2,3 new Company shares for each (1) share of "MITERA SA" that they shall offer to the Company. Approval of the Committee report dated from 21.6.2007 of article 9 of Act 2190/1920 and of the Report of the Board of Directors dated from 27.6.2007 according to article 289, section 1 and 5 of the Stock Exchange Market Regulation. The shares arising from the increase in the Company's share capital shall have a right in the Company's profit in each of its financial years, including the current financial year, according to the applying Legislation. It was decided to introduce the new shares issued as a result of the Company's share capital increase for negotiation in the Athens Stock Exchange. It was decided at the General Meeting that, according to article 13 section 1 of Act 2190/1920, in case the amount of the aforementioned share capital increase is not fully covered, the share capital shall increase up to the amount of coverage.									
5. The Company's Board of Directors was authorized to decide, in its opinion, on the expiration of the payment of the share capital increase and on any relevant date or date of expiry, as well as to settle any issue regarding the drafting of a Prospectus, the granting of licenses and approvals by the Capital Market Committee and the Stock Exchange of Athens and the entry of the new shares in the Athens Stock Exchange. Finally, the BoD was authorized to settle through its decisions any issue regarding the Company's share capital increase, as well as the procedure to arrange any eventual fractional rights according to the applying legislation at issue.									
6. Since February 2007, the Parent company is undergoing a process of regular tax audit regarding financial years 2003, 2004, 2005 and 2006. ALAN MEDICAL SA, its subsidiary, has been audited until financial year 2005 and it has submitted a request to audit financial 2006 (Protocol No. 22063/02.07.07 Tax Office for the Taxation of Societes Anonymes (DOY FAE) Athens). A request for tax audit has also been submitted by subsidiary MAGNETIC PRESENTATIONS SA for financial years 2005 and 2006 (Protocol No. 5973/18.05.07 Athens PEK) as well as subsidiary MITERA HOLDINGS SA (Protocol No. 3668/23.10.06 Tax Office for the Taxation of Societes Anonymes Athens), which has not been tax audited since its foundation, that is since 08.08.2003. ANIZ SA has been tax audited until 2006.									
7. The company has made a cumulative provision of 231.000 euros for legal cases. Substantial surcharges from other litigious or under arbitration disputes and decisions of judicial instruments exceeding the provision already made are not expected to arise.									
8. On 30.06.2007, the Group's staff amounted to 1.134 individuals (30.06.2006: 1.052) and the company's staff amounted to 1.080 (30.06.2006: 1.029).									
9. The cumulative amounts of the company's and the group's purchases/sales (including the income from dividends) from and to affiliated parties from the beginning of the budgetary year, as well as the balances of the company's and the group's liabilities/receivables with the affiliated parties at the end of the current year are presented in the following table:									
					Group Company				
					254,582 993,752				
					3,933,787 3,460,534				
					317,902 549,744				
					12,218,863 15,138,302				
					931,140 855,889				
					20,339 0				
					0 0				

THE VICE-PRESIDENT  
OF THE BOARD OF DIRECTORS

THEM. CHARAMIS  
ID No. AB340781

Marousi, 27 July 2007  
THE CHIEF EXECUTIVE OFFICER

PASCH. BOUCHORIS  
ID No. AA019554

THE DEPUTY  
FINANCE DIRECTOR

EL. KELEPOURI  
ID No. Σ028050

THE HEAD ACCOUNTANT

MICHAEL MANOUSAKIS  
ID No. AB669445